Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Risk adjusted net present value: What is the current valuation of Calidi Biotherapeutics's NNV1?
NNV1 is an oncolytic virus commercialized by Calidi Biotherapeutics, with a leading Phase I program in Recurrent Glioblastoma Multiforme (GBM)....